Ainos, Inc. — 10-Q Summary
Filing identity: The request identifies Ainos, Inc., but the supplied filing is for Amarillo Biosciences, Inc. (OTCBB: AMAR), for the quarter ended June 30, 2012, filed August 9, 2012. The summary below reflects the supplied filing.
Business context and reporting period
Amarillo Biosciences was developing low-dose oral interferon and related products, with a focus on clinical studies and eventual regulatory approval and commercialization. The unaudited filing reports second-quarter and six-month results through June 30, 2012, compared with 2011.
Financial performance and position
| Metric | Three months ended June 30, 2012 | Three months ended June 30, 2011 | Six months ended June 30, 2012 | Six months ended June 30, 2011 |
|---|---|---|---|---|
| Revenue | $240 | $4,835 | $480 | $7,555 |
| Gross margin | $144 (60.0%) | $2,247 (46.5%) | $288 (60.0%) | $3,536 (46.8%) |
| Operating loss | $(145,396) | $(291,533) | $(303,439) | $(488,413) |
| Net loss | $(128,627) | $(328,303) | $(364,741) | $(548,556) |
| Net loss applicable to common shareholders | $(136,725) | $(332,553) | $(379,397) | $(557,012) |
- Second-quarter revenue consisted of $240 in dietary supplement sales; no ACM sales were reported. Six-month revenue was also limited to dietary supplement sales, with no ACM sales.
- Six-month operating cash use was $262,158, versus $178,728 in 2011. Investing cash use was $3,186, primarily for patents; financing provided $266,205. Cash increased by $861 to $3,680.
- At June 30, 2012, total assets were $121,132 and current liabilities were $4,078,978, producing a working-capital deficit of $4,058,854. Stockholders’ deficit was $3,957,846.
- Current liabilities included $2,516,205 in related-party notes payable, $885,924 in accrued related-party interest, $572,830 in accounts payable and accrued expenses, and $25,659 in derivative liabilities. The company reported that two $1 million HBL notes were in repayment default; HBL had not demanded payment.
- Management estimated cash burn at approximately $66,000 per month. Cash paid for interest in the first half was $2,820.
Material changes and unusual items
- Compared with the first half of 2011, revenue fell from $7,555 to $480. Operating expenses declined, including selling, general and administrative expense, which fell 58% to $130,788, and research and development expense, which fell 4% to $172,939.
- Six-month net loss narrowed 34%, mainly reflecting lower expenses. In the second quarter, a $46,285 derivative fair-value gain materially reduced the reported net loss; the filing describes a $22,654 net derivative gain for the first half.
- Noncash and financing activity included $74,091 of common stock issued for convertible debt, $110,300 of preferred stock issued for related-party notes and interest, $23,578 of preferred stock issued for accrued dividends and interest, and forgiveness of $278,259 in accrued salary. The salary release followed an executive contract amendment that reduced annual salary to $60,000.
- Common shares outstanding increased to 73,554,897 from 71,559,789 at year-end 2011. The company also had 14,953,169 shares reserved for options, warrants, or preferred-stock conversion.
- After quarter-end, the CEO advanced an additional $48,440 for working capital between July 3 and July 23, 2012, under a short-term arrangement without a stated due date or interest rate.
Outlook, management commentary, and risks
- Management said continued losses and limited liquidity raise substantial doubt about the company’s ability to continue as a going concern. It sought investor financing and pharmaceutical partners for upfront license fees and clinical-study funding, with no assurance either would be secured. Potential equity financing could substantially dilute existing shareholders or change control.
- The company expected no significant near-term sales or royalty revenue while clinical development and regulatory work remained necessary. Its stated strategy was to pursue Phase 2 studies and seek pharmaceutical partners; management’s anticipated timing for attracting partners was an expectation, not a committed forecast.
- Hepatitis C study preliminary results did not meet the primary endpoint. The company reported a possible benefit in a subgroup with mild liver fibrosis and higher platelet-count normalization in once-daily oral-interferon patients; follow-up studies were being planned. Final study results were expected in the third quarter of 2012.
- For influenza, a Taiwan study was ongoing, with results expected in the second half of 2012. The filing also described publication of results from an earlier Australian study as pending.
- A major supply risk emerged: the company said HBC (formerly HBL) had decided to permanently halt IFN-alpha production and was preparing notice to terminate the agreement. The separate agreement concerning ACM was reportedly unaffected. The filing also cites reliance on third-party manufacturers and distributors, clinical-trial and regulatory uncertainty, competition, intellectual-property risks, and dependence on key personnel.
- The company reported that disclosure controls were effective and that there were no significant changes in internal controls over financial reporting. It reported no legal proceedings known as of the filing date.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is Amarillo Biosciences, Inc., not Ainos, Inc.
- Verify the status and terms of HBC/HBL supply and license arrangements, the production halt, and the defaulted HBL notes.
- Check subsequent financing, cash runway, related-party advances, and whether the company obtained funding or partner support sufficient to continue operations.
- Review final hepatitis C and influenza study results, including the primary-endpoint outcome and whether subgroup findings were confirmed.
- Assess potential dilution from outstanding warrants, options, convertible preferred stock, and any planned equity financing.